Skip to main content
. 2008 Oct 22;116(2):371–378. doi: 10.1007/s10549-008-0161-8

Table 1.

Patients and tumors characteristics by location of aromatase protein expression status at baseline

Characteristics Aromatase protein expression [n (%)]b
Tumor epithelial aromatase Stromal aromatase
Negative Positive Negative Positive
Treatment
    Tamoxifen 24 (53%) 72 (49%) 29 (54) 63 (48)
    Letrozole 21 (47%) 75 (51%) 25 (46) 69 (52)
    P-value 0.6102 0.4605
Age (year) 66.8 67.6 67.6 67
    P-valuec 0.6214 0.6969
Clinical tumor size (cm) 5.7 4.8 5.5 4.7
    P-valuec 0.0144 0.0398
Pre treatment grade
    I 4 (10%) 16 (13%) 4 (8%) 16 (15%)
    II/III 38 (90%) 103 (87%) 47 (92%) 90 (85%)
    P-value 0.5971 0.3064
Pathological tumor size
    ≤20 mm 11 (27%) 44 (32%) 11 (27%) 44 (32%)
    >20 mm 30 (73%) 95 (68%) 30 (73%) 95 (68%)
    P-value 0.5567 0.5567
Pathological node status
    Negative 16 (41%) 55 (43%) 21 (47%) 50 (43%)
    Positive 23 (59%) 72 (57%) 24 (53%) 65 (57%)
    P-value 0.8017 0.7160
HER2 statusa
    Negative 40 (91%) 140 (95%) 50 (93%) 125 (95%)
    Positive 4 (9%) 7 (5%) 4 (7%) 6 (5%)
    P-value 0.2806 0.4810
ER statusc
    Negative 11 (20%) 12 (8%) 14 (20%) 9 (6%)
    Positive 44 (80%) 148 (93%) 55 (80%) 131 (94%)
    P-value 0.0098 0.0027
PgR statusc
    Negative 16 (36%) 48 (33%) 20 (37%) 43 (33%)
    Positive 28 (64%) 98 (67%) 34 (63%) 87 (67%)
    P-value 0.6688 0.6072

aHER2 IHC with fluorescence in situ hybridization confirmation and IHC for ER and PgR were performed as previously described [12]

bAromatase protein expression considered positive if any aromatase IHC staining was present

cFor age and clinical tumor size the student’s t test was used to compare the aromatase positive and negative groups. For binary variables the X2 test was applied with Fisher’s exact test if a count in any cell was less than 5